Cyclopharm
Logotype for Cyclopharm Limited

Cyclopharm (CYC) investor relations material

Cyclopharm H2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cyclopharm Limited
H2 2025 earnings summary27 Mar, 2026

Executive summary

  • Achieved record group revenue of $32.3m in FY2025, up 17% year-over-year, driven by US TechnegasⓇ sales and strong third-party distribution growth.

  • US TechnegasⓇ revenue surged 226% year-over-year, making the US the largest single market for the product.

  • Net loss after tax was $17.2m, reflecting significant investment in US market expansion and foundational infrastructure.

  • Third-party distribution revenue rose 26% to $15.6m, providing diversification and recurring revenue.

  • TechnegasⓇ is now available in 67 countries, with regulatory approval in Colombia secured in December 2025.

Financial highlights

  • Group revenue: $32.33m (up 17% from $27.57m in FY2024).

  • TechnegasⓇ revenue: $16.69m (up 10% year-over-year).

  • Third-party distribution revenue: $15.63m (up 26% year-over-year).

  • Gross margin: $17.9m, stable year-over-year despite evolving revenue mix.

  • Underlying EBITDA: $(15.4)m (vs. $(11.9)m in FY2024).

  • Diluted loss per share: (15.64) cents (vs. (12.83) cents in FY2024).

  • Net cash balance at year-end: $6.6m (down from $20.6m in FY2024).

Outlook and guidance

  • Reaffirmed guidance for 250-300 US TechnegasⓇ installations in the second half of 2026.

  • US market expected to drive exponential growth, with a total addressable market of over US$1 billion annually (US$180m for PE, US$900m for 'Beyond PE' applications).

  • Additional $14m capital raised in Q1 2026 to accelerate US expansion, manufacturing, and clinical development.

  • Ongoing investment in next-generation TechnegasⓇ technology and expansion into broader respiratory indications.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Cyclopharm earnings date

Logotype for Cyclopharm Limited
H1 20261 Sep, 2026
Cyclopharm
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cyclopharm earnings date

Logotype for Cyclopharm Limited
H1 20261 Sep, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Explore our global coverage